Patents Assigned to Alkermes, Inc.
-
Patent number: 9296801Abstract: The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans.Type: GrantFiled: June 6, 2013Date of Patent: March 29, 2016Assignee: Alkermes, Inc.Inventors: Juan Alvarez, Leslie A. McSweeney
-
Patent number: 9156897Abstract: The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.Type: GrantFiled: June 6, 2013Date of Patent: October 13, 2015Assignee: Alkermes, Inc.Inventors: Juan Alvarez, Jean Chamoun, Heather C. Losey
-
Patent number: 9040552Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to mophinan compounds useful as ?, ? and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.Type: GrantFiled: December 4, 2012Date of Patent: May 26, 2015Assignee: Alkermes, Inc.Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf
-
Patent number: 9029543Abstract: The invention relates to a process for the synthesis of quaternized compounds of formula:Type: GrantFiled: April 5, 2012Date of Patent: May 12, 2015Assignee: Alkermes, Inc.Inventor: Scott Duncan
-
Patent number: 8975272Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.Type: GrantFiled: April 10, 2014Date of Patent: March 10, 2015Assignee: Alkermes, Inc.Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
-
Patent number: 8962646Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:Type: GrantFiled: June 29, 2012Date of Patent: February 24, 2015Assignee: Alkermes, Inc.Inventors: Laura Cook Blumberg, Derrick Arnelle
-
Publication number: 20140303200Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.Type: ApplicationFiled: April 10, 2014Publication date: October 9, 2014Applicant: Alkermes, Inc.Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
-
Publication number: 20140275109Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.Type: ApplicationFiled: January 21, 2014Publication date: September 18, 2014Applicant: Alkermes, Inc.Inventor: Josiah Brown
-
Publication number: 20140234962Abstract: The present invention provides fusion polypeptides comprising polypeptide ligands that are modified by circular permutation and fused to at least one polypeptide fusion partner wherein such fusion polypeptides have new, improved or enhanced biological functions or activities. Such improvements include, but are not limited to, increased binding affinity, increased activity, increased agonist activity (super agonist), antagonist activity, increased accessibility, increased flexibility of the active site, increased stability, broader and/or changed substrate specificity, and combinations thereof.Type: ApplicationFiled: February 18, 2014Publication date: August 21, 2014Applicant: Alkermes, Inc.Inventor: Juan Alvarez
-
Publication number: 20140155424Abstract: The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.Type: ApplicationFiled: April 26, 2013Publication date: June 5, 2014Applicant: Alkermes, Inc.Inventor: Alkermes, Inc.
-
Patent number: 8735420Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.Type: GrantFiled: November 30, 2012Date of Patent: May 27, 2014Assignee: Alkermes, Inc.Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
-
Publication number: 20140005215Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to mophinan compounds useful as ?, ? and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.Type: ApplicationFiled: December 4, 2012Publication date: January 2, 2014Applicant: Alkermes, Inc.Inventor: Alkermes, Inc.
-
Publication number: 20130336925Abstract: The invention provides fusion proteins having improved bioactivity comprising a first polypeptide fusion partner and a second polypeptide fusion partner wherein the first fusion partner is linked to the second fusion partner by a mucin-domain polypeptide linker and wherein the bioactivity of the fusion protein of the invention is improved as compared to fusion of the first polypeptide fusion partner and the second polypeptide fusion partner in the absence of the mucin-domain polypeptide linker. Mucin-domain polypeptide linkers comprise a mucin domain that is rich in potential glycosylation sites, and has a high content of serine and/or threonine and proline, which can represent greater than 40% of the amino acids within the mucin domain and further comprise at least about 60% of its mass due to the glycans.Type: ApplicationFiled: June 6, 2013Publication date: December 19, 2013Applicant: Alkermes, Inc.Inventors: JUAN ALVAREZ, LESLIE A. MCSWEENEY
-
Publication number: 20130090343Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.Type: ApplicationFiled: October 10, 2012Publication date: April 11, 2013Applicant: Alkermes, Inc.Inventor: Alkermes, Inc.
-
Patent number: 8389540Abstract: This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.Type: GrantFiled: September 25, 2007Date of Patent: March 5, 2013Assignee: Alkermes, Inc.Inventors: Harry G. Brittain, David A. Dickason, Joyce M. Hotz, Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
-
Patent number: 8354534Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to morphinan compounds useful as ?, ?, and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.Type: GrantFiled: February 13, 2009Date of Patent: January 15, 2013Assignee: Alkermes, Inc.Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf
-
Patent number: 8338428Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.Type: GrantFiled: March 15, 2012Date of Patent: December 25, 2012Assignee: Alkermes, Inc.Inventor: Josiah Brown
-
Patent number: 8338427Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.Type: GrantFiled: October 15, 2008Date of Patent: December 25, 2012Assignee: Alkermes, Inc.Inventor: Josiah Brown
-
Publication number: 20120289516Abstract: The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.Type: ApplicationFiled: March 15, 2012Publication date: November 15, 2012Applicant: ALKERMES, INC.Inventor: Josiah Brown
-
Publication number: 20120258981Abstract: The invention relates to a process for the synthesis of quaternized compounds of formula:Type: ApplicationFiled: April 5, 2012Publication date: October 11, 2012Applicant: Alkermes, Inc.Inventor: Scott Duncan